Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: MicroRNA-708 (miR-708)

February 19, 2015 8:00 AM UTC

In vitro, mouse and patient sample studies suggest increasing miR-708 expression with glucocorticoids could help prevent ovarian cancer metastasis. In invasive ovarian cancer cell lines, vector-induced expression of a miR-708 precursor decreased migration and invasiveness compared with expression of scrambled control miRNA. In a mouse xenograft model of metastatic ovarian cancer, increasing miR-708 expression directly, or by injection of dexamethasone, decreased metastatic burden compared with a control vector or saline. In 82 samples from ovarian cancer patients, high miR-708 expression correlated with increased overall survival and relapse-free survival rates. Next steps include studying glucocorticoids in patients with ovarian cancer...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article